文献速递自身免疫性与大疱性皮肤病

皮肤型红斑狼疮患者动脉粥样硬化性心血管疾病的发生率和患病率

Incidence and Prevalence of Atherosclerotic Cardiovascular Disease in Cutaneous Lupus Erythematosus.
PubMed 文献 · JAMA Dermatol · 2025-01-01

这项回顾性匹配纵向队列研究利用2018年至2020年IBM MarketScan商业索赔数据库,比较了皮肤型红斑狼疮(CLE)、系统性红斑狼疮(SLE)、银屑病患者与无病对照组的动脉粥样硬化性心血管疾病(ASCVD)患病率和发生率。多变量分析显示,CLE患者ASCVD患病 odds 高于对照(OR 1.72),SLE更高(OR 2.41),银屑病无显著差异;随访中位3年,CLE的ASCVD发生风险也高于对照(HR 1.32)。结论认为CLE与ASCVD风险增加相关,临床应考虑加强筛查。

要点

  • CLE患者ASCVD患病 odds 显著高于对照(OR 1.72,95%CI 1.45-2.02)。
  • CLE患者ASCVD发生风险高于对照(HR 1.32,95%CI 1.13-1.55)。
  • 临床应将CLE患者视为ASCVD高风险人群并考虑适当筛查。

核心结论

  • CLE与ASCVD风险增加相关,风险类似于SLE但高于银屑病。
  • 临床医生可考虑将CLE患者视为ASCVD风险增加并实施适当筛查。

研究设计与样本

  • 对照人群为无CLE、SLE和银屑病者,按年龄、性别、保险类型和入组时长与CLE人群10:1匹配。

主要发现

  • 多变量分析中,ASCVD患病 odds 较对照升高见于CLE(OR 1.72,95%CI 1.45-2.02,P<.001)和SLE(OR 2.41,95%CI 2.14-2.70,P<.001),银屑病无显著差异(OR 1.03,95%CI 0.95-1.11,P=.48)。
  • 中位3年随访,ASCVD发生率最高为SLE(24.8/1000人年,95%CI 23.3-26.4),其次CLE(15.2/1000人年,95%CI 13.1-17.7)、银屑病(14.0/1000人年,95%CI 13.5-14.4),对照最低(10.3/1000人年,95%CI 9.77-10.94)。
  • 以对照为参照的多变量Cox回归中,ASCVD发生风险最高为SLE(HR 2.23,95%CI 2.05-2.43,P<.001),其次CLE(HR 1.32,95%CI 1.13-1.55,P<.001),银屑病无显著差异(HR 1.06,95%CI 0.99-1.13,P=.09)。

临床怎么用

  • 治疗CLE患者时可考虑其ASCVD风险增加,并实施适当的筛查测试。
  • 需进一步研究吸烟状态等增加ASCVD风险的合并症的作用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Autoimmune diseases such as systemic lupus erythematosus (SLE) and psoriasis have been previously associated with an increased risk of atherosclerotic cardiovascular disease (ASCVD). Whether similar increased ASCVD risk is seen with cutaneous lupus erythematosus (CLE) remains unclear. OBJECTIVE: To evaluate the incidence and prevalence of ASCVD among those with CLE, SLE, and psoriasis compared with a disease-free control group. DESIGN, SETTING, AND PARTICIPANTS: This retrospective, matched longitudinal cohort study used data from January 2018 to December 2020 in the IBM MarketScan Commercial Claims and Encounters Database. The control population included individuals free of CLE, SLE, and psoriasis, matched 10:1 with the CLE population on age, sex, insurance type, and enrollment duration. Data were analyzed from September 2022 to April 2024. MAIN OUTCOMES AND MEASURES: Prevalent ASCVD was defined as coronary artery disease, prior myocardial infarction, or cerebrovascular accident. Incident ASCVD was assessed through the number of hospitalization events through the end of follow-up (up to 3 years) in each group. Multivariable logistic regression and Cox proportional hazards models were performed to compare the prevalence and incidence of ASCVD between exposure groups, adjusting for age, sex, and cardiovascular risk factors. RESULTS: A total of 8138 persons with CLE (median [IQR] age, 49 [40-47] years; 6618 [81%] female), 24 675 with SLE (median [IQR] age, 46 [36-54] years; 22 432 [91%] female), 192 577 persons with psoriasis (median [IQR] age, 48 [36-56] years; 106 631 [55%] female), and 81 380 control individuals (49 [40-57] years; 66 180 [81%] female) were identified. In multivariable analysis, the odds of ASCVD were higher than control for CLE (odds ratio [OR], 1.72 [95% CI, 1.45-2.02]; P < .001) and SLE (OR, 2.41 [95% CI, 2.14-2.70]; P < .001), but not psoriasis (OR, 1.03 [95% CI, 0.95-1.11]; P = .48). At median 3 years follow-up, incidence rates of ASCVD were highest for SLE (24.8 [95% CI, 23.3-26.4] per 1000 person-years), followed by CLE (15.2 [95% CI, 13.1-17.7] per 1000 person-years), psoriasis (14.0 [95% CI, 13.5-14.4] per 1000 person-years), and then controls (10.3 [95% CI, 9.77-10.94] per 1000 person-years). In multivariable Cox proportional regression modeling with the control group as a reference group, the highest risk of incident ASCVD was in those with SLE (hazard ratio [HR], 2.23 [95% CI, 2.05-2.43]; P < .001), followed by CLE (HR, 1.32 [95% CI, 1.13-1.55]; P < .001), and psoriasis (HR, 1.06 [95% CI, 0.99-1.13]; P = .09). CONCLUSIONS AND RELEVANCE: In this retrospective matched longitudinal cohort study, CLE was associated with an increased risk for ASCVD, similar to the risk in SLE but higher than the risk in psoriasis. The role of comorbidities that augment ASCVD risk like smoking status should be further investigated. Clinicians treating patients with CLE can consider them at increased ASCVD risk and institute appropriate screening tests.

来源:JAMA Dermatol,查看原文。版权归原作者所有。

引用

  1. Chen HW, Liu J, Yang DM, et al. Incidence and Prevalence of Atherosclerotic Cardiovascular Disease in Cutaneous Lupus Erythematosus. JAMA Dermatol. 2025. PMID: 39630434. doi:10.1001/jamadermatol.2024.4991

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。